FDA Approved: SEGLUROMET — Supplemental Application (Merck Sharp & Dohme LLC)

View source ↗

Summary

The FDA approved a supplemental application for Segluromet, a fixed-dose combination of ertugliflozin and metformin hydrochloride by Merck Sharp & Dohme LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• SEGLUROMET (ertugliflozin and metformin hydrochloride)

Snippet

SUPPL AP for SEGLUROMET (ERTUGLIFLOZIN AND METFORMIN HYDROCHLORIDE)